AMG-510, also known as sotorasib, is a groundbreaking therapeutic agent primarily utilized in the treatment of non-small cell lung cancer (NSCLC) with a specific genetic mutation known as KRAS G12C. This mutation is present in a significant subset of NSCLC patients and has historically been challenging to target with conventional therapies. AMG-510 works by selectively inhibiting the mutant KRAS protein, effectively halting the uncontrolled cell proliferation driven by this mutation. Its application has shown promising results in clinical trials, offering hope for patients with this previously untreatable form of lung cancer. Additionally, research is ongoing to explore its potential efficacy in other cancers harboring the KRAS G12C mutation, such as colorectal cancer and pancreatic cancer. The development of AMG-510 represents a significant advancement in precision medicine, providing a targeted approach to cancer treatment that improves outcomes and quality of life for patients.